More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...
About 140 million Americans, more than half of the nation's adults, could be considered candidates for weight loss drugs ...
More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Analysts look at the likelihood of lawmakers making moves to rein in drug middlemen this session. Also, covid-era prescription flexibility is kept in place, pharmaceutical companies take on GLP-1 ...
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...
In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia–but for patients, on GLP-1’s there may still be ...
Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...
Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback